Nuvectis Pharma, Inc. (NVCT) Stock Analysis and Metrics

Sector: Healthcare Industry: Biotechnology CIK: 0001875558

P/B 6.50

P/E -5.61

P/S 0.00

Market Cap 156.07 Mn

ROIC (Qtr) -129.18

Div Yield % 0.00

Rev 1y % (Qtr) 0.00

Total Debt (Qtr) 0.00

Debt/Equity (Qtr) 0.00

About

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, operates in the development of innovative precision medicines for the treatment of severe conditions of unmet medical need in oncology. Its main business activities revolve around the development of drug candidates in the precision medicine space, focusing on cancer-promoting factors and clinical landscape and regulatory requirements. Nuvectis Pharma generates revenue through the development and commercialization of its product candidates, including NXP800 and NXP900. NXP800 is...

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, operates in the development of innovative precision medicines for the treatment of severe conditions of unmet medical need in oncology. Its main business activities revolve around the development of drug candidates in the precision medicine space, focusing on cancer-promoting factors and clinical landscape and regulatory requirements.

Nuvectis Pharma generates revenue through the development and commercialization of its product candidates, including NXP800 and NXP900. NXP800 is a small molecule product candidate that activates the GCN2 kinase, inducing inhibition of cap-dependent protein translation and activation of the integrated stress response, leading to cancer cell death. NXP800 has shown promising results in preclinical studies, including inhibition of tumor growth in xenograft models of ovarian cancer and cholangiocarcinoma. The company is currently evaluating the safety and efficacy of NXP800 in a Phase 1 clinical trial in patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.

NXP900 is a targeted therapy, small molecule SRC and YES1 kinase inhibitor product candidate that has shown anti-tumor activity in preclinical studies. The company is currently developing NXP900 through clinical trials, with the goal of obtaining regulatory approval for its use in treating solid tumors. NXP900 has shown promising results in preclinical studies, including inhibition of tumor growth in xenograft models of breast, esophageal, and head and neck cancers.

Nuvectis Pharma's position within the industry is strong, with a focus on precision medicine and a pipeline of product candidates that have shown promising results in preclinical studies. The company's key competitors include other biopharmaceutical companies that are also developing precision medicine products for the treatment of cancer, such as ImmunoGen, Inc. and MorphoSys AG. However, Nuvectis Pharma's commitment to developing innovative treatments for cancer and its strong intellectual property portfolio, including patents and patent applications related to NXP800 and NXP900, position it well for future growth and success.

The company's customers include patients with cancer who are in need of effective and targeted treatments. Nuvectis Pharma is committed to developing products that address unmet medical needs and improve patient outcomes.

In addition to its product candidates, Nuvectis Pharma has a strong intellectual property portfolio, with patents and patent applications in place to protect its technology and products. The company has licensed intellectual property from the Institute for Cancer Research (ICR) and the University of Edinburgh, and has entered into agreements with these institutions to collaborate on the development of its product candidates.

Overall, Nuvectis Pharma is a promising biopharmaceutical company with a strong pipeline of product candidates and a focus on precision medicine. The company's commitment to developing innovative treatments for cancer and its strong intellectual property portfolio position it well for future growth and success.

Stock Price Chart

Analysis

Pros

Cash position of 35.44M provides exceptional 14.59x coverage of minority interest expenses 2.43M, indicating strong liquidity.
Tangible assets of 35.59M provide robust 6.93x coverage of other current liabilities 5.14M, indicating strong asset backing.
Cash reserves of 35.44M provide robust 3.06x coverage of current liabilities 11.58M, indicating strong short-term solvency.
Strong cash position of 35.44M provides 6.90x coverage of other current liabilities 5.14M, indicating excellent liquidity.
Cash position of 35.44M represents healthy 1.48x of working capital 24.01M, demonstrating strong operational liquidity.

Cons

Investment activities of 0 provide weak support for R&D spending of 17.56M, which is 0x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
High financing cash flow of 32.77M relative to working capital of 24.01M, which is 1.36x suggests concerning dependence on external funding for operational needs.
Operating cash flow of (14.50M) is outpaced by equity issuance of 32.77M (-0.44 ratio), indicating concerning reliance on equity markets for funding operations.
Operating cash flow of (14.50M) shows concerning coverage of minority interest expenses of 2.43M, which is -5.97x, suggesting complex corporate structure risks.
Tangible assets of 35.59M provide limited backing for working capital of 24.01M, which is 1.48x, suggesting increased operational risk in market downturns.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	SMMT	Summit Therapeutics Inc.	1,323.29 Bn	-1,435.83	0.00	0.01 Bn
2	ONC	BeOne Medicines Ltd.	417.21 Bn	6,086.20	83.90	1.90 Bn
3	VRTX	Vertex Pharmaceuticals Inc / Ma	116.84 Bn	31.79	9.97	1.83 Bn
4	REGN	Regeneron Pharmaceuticals, Inc.	78.64 Bn	17.18	5.52	2.71 Bn
5	ALNY	Alnylam Pharmaceuticals, Inc.	54.97 Bn	1,261.84	17.12	3.21 Bn
6	ARGX	Argenx Se	51.25 Bn	34.02	26,727.15	-
7	BNTC	Benitec Biopharma Inc.	43.25 Bn	-1,034.17	0.00	0.00 Bn
8	INSM	INSMED Inc	38.50 Bn	-32.52	86.13	0.74 Bn

Industry Comparisons

Current Valuation

Metric	Value	Industry
EV to Assets	3.63	12.03
EV to Cash from Ops.	-8.92	24.32
EV to Debt	0.00	730.11
EV to EBIT	-4.65	-10.85
EV to EBITDA	-4.90	7.07
EV to Free Cash Flow [EV/FCF]	-8.92	22.90
EV to Market Cap	0.83	80.68
EV to Revenue	0.00	219.46
Price to Book Value [P/B]	6.50	21.99
Price to Earnings [P/E]	-5.61	-12.59

Dividend Metrics

Metric	Value	Industry	Percentile
Dividend Coverage Ratio	0.00	-11.94
Dividend Payout Ratio %	0.00	0.16
Dividend per Basic Share	0.00	0.01
FCF Dividend Payout Ratio %	0.00	-0.14
Interest Coverage	0.00	841.02

Growth Metrics

Metric	Value	Industry
Capex Growth (1y) %	0.00	-27.16
Cash and Equivalents Growth (1y) %	106.43	734.69
Dividend Growth (1y) %	0.00	0.01
EBIAT Growth (1y) %	-43.52	-46.35
EBITDA Growth (1y) %	-30.31	-1.81
EBIT Growth (1y) %	-43.52	-55.92
EBT Growth (1y) %	-43.52	-12.18
EPS Growth (1y) %	-18.10	-27.84
FCF Growth (1y) %	-6.37	-32.19
Gross Profit Growth (1y) %	0.00	226.86

Liquidity Ratios

Metric	Value	Industry
Asset Utilization Ratio	0.00	0.14
Cash Payout Ratio	0.00	0.00
Cash Ratio	3.06	3.86
Current Ratio	3.07	7.28
Debt to Equity Ratio	0.00	0.41
Interest Cover Ratio	0.00	841.02
Times Interest Earned	0.00	841.02

Profitability

Metric	Value	Industry	Percentile
EBITDA Margin %	0.00	-18,230.47
EBIT Margin %	0.00	-18,577.52
EBT Margin %	0.00	-19,484.48
Gross Margin %	0.00	-7.76
Net Profit Margin %	0.00	-19,434.96

Nuvectis Pharma, Inc. (NASDAQ: NVCT)